Royal Bank of Canada
SBFM

Royal Bank of Canada’s Sunshine Biopharma SBFM Stock Holding History

Royal Bank of Canada’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$4K – 7474
2024
Q1 		$4K Buy
+3
New +$8.81K ﹤0.01% 6527

Other funds holding SBFM

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

Royal Bank of Canada's SBFM Position: Q2 2024 in Review

Royal Bank of Canada sold out of Sunshine Biopharma (SBFM) in Q2 2024, closing a stake of 3 shares — an estimated $4K sold.

Royal Bank of Canada first reported a position in SBFM in Q1 2024 and held it in 1 quarter. The position peaked at $4K in Q1 2024. 8 funds tracked by Wall St. Rank hold SBFM as of Q2 2024.

  • Royal Bank of Canada reported no remaining Sunshine Biopharma position as of Q2 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 3 Sunshine Biopharma shares in Q2 2024, an estimated $4K.
  • Royal Bank of Canada first reported a position in Sunshine Biopharma in Q1 2024 and held it in 1 quarter.
  • Royal Bank of Canada's Sunshine Biopharma position peaked at $4K in Q1 2024.
  • 8 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2024.

Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.